Press Release FeedGet the RSS feed
Menu

Business Wire

AHF Blasts PhRMA for Attacks On, and Noncompliance with 340B Program

Business Wire

HRSA review finds 4 out of 5 drugmakers out of compliance with mandatory discount drug pricing

WASHINGTON, October 19, 2026--In response to news in the 340B Report last week that was highly critical of the drug industry's noncompliance with compulsory elements of the 340B drug pricing program, AIDS Healthcare Foundation (AHF) released the following statement:

"Drug companies relentlessly attack the safety net providers that participate in the 340B program, demanding more restrictions and oversight by HRSA. But HRSA's recent audit results show that drug-companies' saber-rattling is really a diversion – meant to keep eyes off their own noncompliance with their statutory obligations to provide discounted prices to safety net providers," said Laura Boudreau, AHF Chief of Operations, Risk Management and Quality Improvement. "Rather than entertain PhRMA's 340B 'solutions' in search of a problem, we should let HRSA continue to do its important work and let the 340B program be."

AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 3.3 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261019346463/en/

Contacts

Ged Kenslea, Senior Director, AHF Communications
(323) 791-5526 c [email protected]

  1. CybersecurityZumigo, Inc.Zumigo InstaAuth Achieves FIDO2 Server Certification, Bringing Frictionless, Secure Passkey Sign-In to Banks, Fintechs, and MerchantsFull certification from the FIDO Alliance validates InstaAuth's phishing-resistant passkey authentication across real-world devices, available now in the Auth Widget and IDV Builder SAN JOSE, Calif., October 19, 2026--Zumigo, Inc., a leader in mobile identity intelligence and fraud prevention, today an
  2. FinanceXencor, Inc.Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaPASADENA, Calif., October 19, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1
  3. FinanceNRG Energy, Inc.NRG Energy, Inc. Announces Quarterly DividendCompanies: NRG EnergyHOUSTON, October 19, 2026--NRG Energy, Inc. (NYSE: NRG) today announced that its Board of Directors declared a quarterly dividend on the Company's common stock of $0.475 per share, or $1.90 per share on an annualized basis. The dividend is payable on November 16, 2026, to stockholders of record as of N
  4. HealthcareFrontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026BOSTON & SOUTH SAN FRANCISCO, Calif., October 19, 2026--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will pr
  5. FinanceTaiho Oncology, Inc. and Cullinan Therapeutics, Inc.Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesIntracranial Objective Response Rate of 30.2% was observed in 43 evaluable patients Results to be shared in poster presentation at ESMO Congress 2026 PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Co
  6. FinanceBlackSky Technology Inc.BlackSky to Host Third Quarter 2026 Results Conference CallHERNDON, Va., October 19, 2026--BlackSky Technology Inc. (NYSE: BKSY ) will host a live webcast and conference call to discuss third quarter 2026 financial results and its business outlook on Thursday, November 5, 2026, at 8:30 a.m. EST. A press release with BlackSky's financial results will be release